| Name | Title | Contact Details |
|---|
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
NextPhase Medical Device — Medical Device Contract Manufacturing Company–Your single source contract manufacturing company for medical device design, development, manufacturing, assembly, and complete supply chain management. We specialize in Sterile S...
TCG employs a team of pharmacy designers and industrial engineers who can help with the integration of automation or storage and retrieval solutions that will meet the business needs of the pharmacy.
Improving the lives of people with severe illness or injury takes more than skill and compassion - it takes innovation. A national leader in long term acute care, LifeCare was built on the belief that early and aggressive intervention, coupled with a personalized treatment plan that encompasses body, mind and soul, can maximize a patient`s potential for recovery. Our multi-disciplinary treatment teams are directed by highly-trained, committed physicians and include healthcare professionals involved in all aspects of a patient`s care: nurses, respiratory therapists, physical medicine specialists, radiologists, pharmacists, dietitians and case managers. Our philosophy has impacted the lives of thousands of LifeCare patients, resulting in improved outcomes, shorter hospital stays and more cost-effective treatment. Based in Plano, Texas, the LifeCare Family of Hospitals includes both freestanding and "hospital-in-hospital" acute care hospitals designed to treat medically complex patients who require acute care hospital services for an extended period of time. Currently, our network includes 24 locations in 9 states.
TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.